axid capsules hard 150 milligram
b & s healthcare - nizatidine - capsules hard - 150 milligram
dbl dobutamine injection
hospira australia pty ltd - dobutamine hydrochloride -
dobutamine sandoz
sandoz pty ltd - dobutamine hydrochloride -
dobutrex
aspen pharmacare australia pty ltd - dobutamine hydrochloride -
nizac
aspen pharmacare australia pty ltd - nizatidine -
ropivacaine actavis
actavis australia pty ltd - ropivacaine hydrochloride monohydrate; ropivacaine hydrochloride -
tacidine
alphapharm pty ltd - nizatidine -
tazac (aspen)
aspen pharmacare australia pty ltd - nizatidine -
dbl™ flucloxacillin sodium powder for injection
pfizer new zealand limited - flucloxacillin sodium monohydrate 1.05 g equivalent to 1 g flucloxicillin.; - powder for injection - 1 g - active: flucloxacillin sodium monohydrate 1.05 g equivalent to 1 g flucloxicillin. - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections.
norvir
abbvie limited - ritonavir 80 mg/ml - oral solution - 80 mg/ml - active: ritonavir 80 mg/ml excipient: caramel citric acid ethanol peppermint oil polyoxyl 35 castor oil propylene glycol purified water saccharin sodium sunset yellow fcf - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.